SEGA‐like circumscribed astrocytoma in a non‐NF1 patient, harboring molecular profile of GBM. A case report

Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC)

(2022) Peter Horak et al.   GENETICS IN MEDICINE

Subependymal Giant Cell Astrocytoma in a 79-Year-Old Woman without Clinical Features of Tuberous Sclerosis: A Case Report

(2020) Misha Movahed-Ezazi et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas

(2018) Drew Pratt et al.   ACTA NEUROPATHOLOGICA

cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant

(2018) David N. Louis et al.   ACTA NEUROPATHOLOGICA

Subependymal giant cell astrocytoma-like astrocytoma: a neoplasm with a distinct phenotype and frequent neurofibromatosis type-1-association

(2018) Doreen N. Palsgrove et al.   MODERN PATHOLOGY

DNA methylation-based classification of central nervous system tumours

(2018) David Capper et al.   NATURE

cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV”

(2018) Daniel J. Brat et al.   ACTA NEUROPATHOLOGICA

Subependymal giant cell astrocytomas in Tuberous Sclerosis Complex have consistent TSC1/TSC2 biallelic inactivation, and no BRAF mutations

(2017) Anika Bongaarts et al.   Oncotarget

Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study

(2016) David N. Franz et al.   PLoS One

Pleomorphic xanthoastrocytoma: report of two cases with unconventional clinical presentations

(2014) M. Adelita Vizcaíno et al.   CLINICAL NEUROPATHOLOGY

Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study

(2014) David Neal Franz et al.   LANCET ONCOLOGY

Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial

(2012) David Neal Franz et al.   LANCET

Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner

(2011) S. Banerjee et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Gliomas in Neurofibromatosis Type 1: A Clinicopathologic Study of 100 Patients

(2008) Fausto J. Rodriguez et al.   JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY

Subependymal giant cell astrocytoma (SEGA): Is it an astrocytoma? Morphological, immunohistochemical and ultrastructural study

(2008) Anna M. Buccoliero et al.   NEUROPATHOLOGY

Solitary subependymal giant cell astrocytoma incidentally found at autopsy in an elderly woman without tuberous sclerosis complex

(2008) Hidehiro Takei et al.   NEUROPATHOLOGY